Presentation is loading. Please wait.

Presentation is loading. Please wait.

J. Mehilli, A. Kastrati, K. Huber, S. Schulz, J. Pache, C.Markwardt, S. Kufner, F. Dotzer, K. Schlotterbeck, J. Dirschinger, A. Schömig. Abciximab in Patients.

Similar presentations


Presentation on theme: "J. Mehilli, A. Kastrati, K. Huber, S. Schulz, J. Pache, C.Markwardt, S. Kufner, F. Dotzer, K. Schlotterbeck, J. Dirschinger, A. Schömig. Abciximab in Patients."— Presentation transcript:

1 J. Mehilli, A. Kastrati, K. Huber, S. Schulz, J. Pache, C.Markwardt, S. Kufner, F. Dotzer, K. Schlotterbeck, J. Dirschinger, A. Schömig. Abciximab in Patients with AMI Undergoing Primary PCI After Clopidogrel Pretreatment BRAVE-3 Trial Bavarian Reperfusion AlternatiVes Evaluation-3 Trial ClinicalTrials.gov Identifier: NCT

2 Background  Glycoprotein IIb/IIIa inhibitors (GPI) may improve the results of primary PCI in acute STEMI  Pretreatment with a 300mg loading dose of clopidogrel improved the outcome of patients undergoing PCI in the setting of the CLARITY trial  A higher, 600mg loading dose of clopidogrel further enhances and accelerates platelet inhibition

3 Objective..to assess whether abciximab further reduces the infarct size in patients with acute ST-elevation myocardial infarction undergoing PCI after pretreatment with 600 mg clopidogrel

4 Endpoints  Final infarct size (% of the left ventricle) SPECT study (5-7 days after randomization) Primary endpoint: Myocardial perfusion % 100% 0% 50% Secondary endpoints:  Death  Myocardial reinfarction  Urgent revascularization  Stroke  Major and minor bleedings (TIMI criteria)  Profound thrombocytopenia

5 Clopidogrel 600 mg oral Aspirin 500 mg i.v. or oral Unfractionated Heparin 5000 IE Study Therapy (randomized, double-blind, multicenter) Placebo n=399 Abciximab n=401 Aspirin 200mg/day indefinitely Clopidogrel 2 x 75mg/day for 3 days Clopidogrel 75mg/day for at least 4 weeks

6 Reperfusion Strategy % AbciximabPlacebo Drug-eluting stents Bare metal stents PTCA Medical treatment P =.80

7 Primary Endpoint % LV AbciximabPlacebo Final infarct size Median [25th; 75th percentile] Final infarct size Mean % LV P =.47 AbciximabPlacebo P =

8 30-Day Mortality Days after randomization Cumulative Incidence Abciximab Placebo P =.53 6 %

9 Conclusion In patients with acute STEMI undergoing primary PCI after pre-treatment with a 600mg loading dose of clopidogrel, the additional use of abciximab is not associated with further reduction in infarct size


Download ppt "J. Mehilli, A. Kastrati, K. Huber, S. Schulz, J. Pache, C.Markwardt, S. Kufner, F. Dotzer, K. Schlotterbeck, J. Dirschinger, A. Schömig. Abciximab in Patients."

Similar presentations


Ads by Google